Erie Indemnity Stock: Is ERIE Underperforming the Financial Sector?
Erie, Pennsylvania-based Erie Indemnity Company (ERIE) serves as the attorney-in-fact for the subscribers at the Erie Insurance Exchange, which is a reciprocal insurer that writes property and casualty insurance. With a market cap of $16.1 billion, the company provides issuance and renewal services, sales-related services, and underwriting services.
Companies valued at $10 billion or more are generally classified as 'large-cap' stocks, and Erie Indemnity Company fits this description perfectly. The company offers strong customer service and a regional focus, supporting a network of independent insurance agents and providing a wide range of personal and commercial insurance products.
Dear Tesla Stock Fans, Mark Your Calendars for June 30
3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio
Nvidia Is Quickly Approaching a New Record High. Is It Too Late to Buy NVDA Stock?
Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today!
Shares of Erie Indemnity have dipped 36.3% from its 52-week high of $547. ERIE stock has dropped 16.6% over the past three months, lagging behind the Financial Select Sector SPDR Fund's (XLF) 2.4% increase.
In the long term, ERIE stock has dipped 15.4% on a YTD basis, whereas XLF has risen 3.9%. Additionally, over the past 52 weeks, shares of NTAP have decreased 2.3%, underperforming XLF's 21.7% return.
The stock has been trading below its 50-day moving average since late April. Also, despite some fluctuations, the stock has been trading below its 200-day moving average since early December last year.
Shares of ERIE tumbled 11.5% following the release of its mixed Q1 2025 results on Apr. 24. Driven by a 13.4% increase in management fee revenue and a 29% jump in investment income, its quarterly revenue rose 12.3% from the year-ago quarter to $989.4 million, exceeding Street forecasts. However, EPS came in at $2.65, a 11.3% year-over-year increase, but missed analysts' estimates, which dampened investor sentiment.
Compared to its peer, Willis Towers Watson Public Limited Company (WTW) has outpaced ERIE stock. Shares of WTW have declined 5% on a YTD basis and gained 16.5% over the past 52 weeks.
Although ERIE has underperformed relative to the sector, analysts are moderately optimistic about its stock's prospects. ERIE has a consensus rating of 'Moderate Buy' from the two analysts covering the stock, and as of writing, it is trading notably above the mean price target of $73.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Sugar Prices Supported by News of Increased Pakistan Sugar Imports
July NY world sugar #11 (SBN25) Friday closed up +0.22 (+1.39%), and August London ICE white sugar #5 (SWQ25) closed down -7.30 (-1.51%). Sugar prices on Friday settled mixed. Short covering emerged in sugar futures on Friday after Pakistan's government announced plans to import 250,000 metric tons of raw sugar due to a disappointing sugarcane harvest. The dollar's weakness (DXY00) on Friday also prompted some short covering in sugar futures. Drought Conditions Are Setting In. How Much Higher Can Wheat Prices Go? Coffee Prices Sharply Lower as Global Supply Concerns Ease Cocoa Prices Plunge as Beneficial Rain in West Africa Boosts Crop Conditions Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Sugar prices have fallen over the past 3-months and posted 4-year nearest-futures lows on Wednesday due to expectations of a global sugar surplus. On May 22, the USDA, in its biannual report, projected that global 2025/26 sugar production would increase by +4.7% year-over-year (y/y) to a record 189.318 million metric tons (MMT), with a global sugar surplus of 41.188 MMT, up 7.5% year-over-year. The outlook for higher sugar production in India, the world's second-largest producer, is bearish for prices. On June 2, India's National Federation of Cooperative Sugar Factories projected that India's 2025/26 sugar production would climb +19% y/y to 35 MMT, citing larger planted cane acreage. The outlook for abundant rainfall in India could lead to a bumper sugar crop, which is bearish for prices. On April 15, India's Ministry of Earth Sciences projected an above-normal monsoon this year, with total rainfall forecast to be 105% of the long-term average. India's monsoon season runs from June through September. Signs of larger global sugar output are negative for prices. On May 22, the USDA's Foreign Agricultural Service (FAS) predicted that Brazil's 2025/26 sugar production would rise +2.3% y/y to a record 44.7 MMT. Also, India's 2025/26 sugar production is projected to rise +25% y/y to 35.3 MMT, citing favorable monsoon rains and increased sugar acreage. In addition, Thailand's 2025/26 sugar production is expected to climb +2% y/y to 10.3 MMT. In a bearish factor, the Indian government said on January 20 that it would allow its sugar mills to export 1 MMT of sugar this season, easing the restrictions placed on sugar exports in 2023. India has restricted sugar exports since October 2023 to maintain adequate domestic supplies. India allowed mills to export only 6.1 MMT of sugar during the 2022/23 season to September 30 after allowing exports of a record 11.1 MMT in the previous season. However, the ISMA projects that India's 2024/25 sugar production will fall -17.5% y/y to a 5-year low of 26.2 MMT. Also, the ISMA reported last Monday that India's sugar production from Oct 1-May 15 was 25.74 MMT, down -17% from the same period last year. In addition, Indian Food Secretary Chopra said on May 1 that India's 2024/25 sugar exports may only total 800,000 MT, below earlier expectations of 1 MMT. The outlook for higher sugar production in Thailand is bearish for sugar prices. On May 2, Thailand's Office of the Cane and Sugar Board reported that Thailand's 2024/25 sugar production rose +14% y/y to 10.00 MMT. Thailand is the world's third-largest sugar producer and the second-largest exporter of sugar. Sugar prices have some support from reduced sugar production in Brazil. Unica reported Monday that cumulative 2025/26 Brazil Center-South sugar output through May is down by -11.6% y/y to 6.954 MMT. Last month, Conab, Brazil's government crop forecasting agency, said 2024/25 Brazil sugar production fell -3.4% y/y to 44.118 MMT, citing lower sugarcane yields due to drought and excessive heat. The International Sugar Organization (ISO) raised its 2024/25 global sugar deficit forecast to a 9-year high of -5.47 MMT on May 15, up from a February forecast of -4.88 MMT. This indicates a tightening market following the 2023/24 global sugar surplus of 1.31 MMT. ISO also cut its 2024/25 global sugar production forecast to 174.8 MMT from a February forecast of 175.5 MMT. The USDA, in its bi-annual report released May 22, projected that global 2025/26 sugar production would climb +4.7% y/y to a record 189.318 MMT and that global 2025/26 human sugar consumption would increase +1.4% y/y to a record 177.921 MMT. The USDA also forecasted that 2025/26 global sugar ending stocks would climb +7.5% y/y to 41.188 MMT. On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
A $1.3 Billion Reason to Buy Eli Lilly Stock Now
Eli Lilly (LLY) is a pharmaceutical company that focuses on cardiometabolic health, neuroscience, oncology, and immunology. The company markets its products through brands like Jardiance, Emgality, Humalog, Mounjaro, and Trulicity. Eli Lilly was founded in 1876 and operates in 125 countries with its headquarters in Indianapolis, Indiana. Dear Tesla Stock Fans, Mark Your Calendars for June 30 3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio This Options Tool Can Show You How to Trade Tesla Stock Ahead of Robotaxi Day Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Eli Lilly has shown notable volatility in the medium term. Over the past month, the stock has gained 2.3%, however shares are down 1% in the year to date. The stock remains 21.4% below its 52-week high while registering a 13.7% slip in the past 52 weeks. Eli Lilly posted its first-quarter results back on May 1. The company reported a profit of $3.34 per adjusted share, widely missing analysts' $3.52 estimate. The company generated $12.73 billion in revenue, a significant 45% rise from the same quarter last year and beating Wall Street's $12.62 billion estimate. Revenue from Mounjaro saw a substantial rise of 113% year over year to $3.84 billion. Zepbound produced $2.31 billion revenue, registering 20.9% growth. Shares of Eli Lilly fell more than 11% on the results as investors focused on the revised guidance. The company lowered its profit forecast with adjusted EPS now expected in the range of $20.78 to $22.28 from the previous range of $22.50 to $24.00 per adjusted share. The company cites heightened acquired in-process research and development charges (IPR&D) as one of the reasons for the guidance cut. Eli Lilly has announced an agreement to acquire gene-editing company Verve Therapeutics (VERV) for $1.3 billion. This values Verve Therapeutics at $10.50 per share, reflecting a 67.5% premium to its pre-announcement closing price. The move comes as part of Eli Lilly's plans to diversify the company's operations beyond diabetes and weight-loss drugs. Eli Lilly will pay $1 billion upfront and an additional $300 million contingent upon Verve Therapeutics' ability to achieve certain clinical targets. The companies were already involved in a partnership aimed at utilizing gene-editing treatment to lower cholesterol levels in cardiovascular patients. Verve Therapeutics' gene-editing technique utilizes cutting-edge technology allowing it to execute precise one-time changes to the DNA. This can deactivate genes such as PCSK9, LPA, and ANGPTL3, contributing to high cholesterol levels. At present the company is undergoing early stage clinical trials in patients diagnosed with familial hypercholesterolemia, a genetic disorder that causes high levels of LDL cholesterol. Eli Lilly is a top-rated pharmaceutical stock with a consensus 'Strong Buy' rating from analysts. Its mean price target is $983.12, reflecting upside potential of nearly 29%. The stock is covered by 26 analysts and has received 20 'Strong Buy' ratings, two 'Moderate Buy' ratings, and four 'Hold' ratings from Wall Street. On the date of publication, Ruchi Gupta did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
35 minutes ago
- Yahoo
Is Apollo Global Management Stock Outperforming the Dow?
Apollo Global Management, Inc. (APO) is a leading global alternative asset manager headquartered in New York City. With a market cap of $76.1 billion, it specializes in credit, private equity, real estate, infrastructure, and secondary, serving institutional and individual investors worldwide. Companies valued at $10 billion or more are generally considered 'large-cap' stocks, and Apollo Global Management fits this criterion perfectly. The firm's ability to generate consistent fee-related and spread-related earnings, even in volatile markets, reflects its disciplined investment approach and deep credit expertise. Apollo's strong dealmaking capabilities, global expansion, and record asset inflows further reinforce its leadership in the alternative asset space, positioning it for sustained growth and strategic flexibility. Is Palantir Stock Poised to Surge Amidst the Israel-Iran Conflict? 'It Has No Utility': Warren Buffett Doesn't Care How High Gold Goes, He Isn't a Buyer OpenAI CEO Sam Altman Says 'We Are Heading Towards a World Where AI Will Just Have Unbelievable Context on Your Life' Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. However, the asset manager has fallen nearly 29.8% from its 52-week high of $189.49 met on Dec. 9. Apollo Global Management shares have declined 3.2% over the past three months, lagging behind the broader Dow Jones Industrial Average's ($DOWI) 1.4% rise during the same time frame. APO shares have declined 19.4% year-to-date, underperforming the Dow Jones Industrial Average's marginal pullback during the same period. However, over the past 12 months, Apollo Global Management has delivered a solid 13.4% return, outpacing the Dow's 8.6% gain and showcasing its longer-term strength. APO has been trading below its 200-day moving averages since late March but has edged above the 50-day moving average since early June. Apollo Global's shares slipped 1.8% on May 2 after posting Q1 results that weighed on investor sentiment. A significant drag came from its Retirement Services unit, which recorded $828 million in investment-related losses, marking a sharp contrast to the $1.7 billion gain reported in the prior-year quarter. As a result, total revenue fell 21.2% year-over-year to $5.5 billion. While adjusted net income rose 5.2% to $1.1 billion, the figure missed Wall Street estimates, contributing to the market's muted reaction. However, in contrast, rival Blackstone Inc. (BX) has underperformed APO, dipping 20.3% on a YTD basis, and 11.9% rise over the past year Thanks to APO's strong performance over the past year, analyst sentiment remains decidedly bullish. Of the 22 analysts tracking the stock, the consensus rating is a 'Strong Buy,' with a mean price target of $159.90 indicating a potential upswing of 20.1% from the current market prices. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
